iCeutica Inc. and Nordic Biotech Sign an Agreement to Reformulate and Commercialise Nano-Compounds Using iCeutica Inc.'s EON(TM) Platform

Published: May 09, 2007

PHILADELPHIA--(BUSINESS WIRE)--iCeutica Inc is pleased to announce that it has signed a binding agreement with Danish venture capital group Nordic Biotech to establish a new company Spree Pharma A/S. The agreement enables Spree to leverage iCeutica’s proprietary Encapsulated Organic Nanoparticle (EON) Platform to reformulate a number of compounds for launch and marketing by Spree Pharma A/S in focused therapeutic indications.

Back to news